Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Phase 3YCANTHPositive

AI Analysis

Summary

Verrica Pharmaceuticals announced completion of enrollment in the COVE-2 Phase 3 pivotal trial evaluating YCANTH for common warts treatment, with topline data expected in Q1 2027. An interim statistical power analysis confirmed no additional patients are needed for full enrollment.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Enrollment completed in COVE-2 pivotal trial; per-protocol interim statistical power analysis confirms no additional patients needed

Importance:7/10

Sentiment:

0.60

Phase 3enrollment completetopline data pendingYCANTHcommon warts

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Pharma on August 27, 2026 12:00 PM

Read Original